Eversana Eversana Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Eversana Eversana Pharmaceutical Import Records from India — 5 Products, $5.6M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Eversana Eversana — Pharmaceutical Importer Profile (2026) | 5 Products, $5.6M Trade | TransData Nexus

Eversana Eversana

Pharmaceutical Importer · United States · Cardiovascular Focus · $5.6M Total Trade · DGFT Verified

Eversana Eversana is a pharmaceutical importer based in United States with a total trade value of $5.6M across 5 products in 4 therapeutic categories. Based on 112 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Eversana Eversana sources from 1 verified Indian supplier, with Gland Pharma Limited accounting for 100.0% of imports.

Eversana Eversana — Import Portfolio & Supplier Network

Eversana Eversana import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Eversana Eversana?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Gland Pharma Limited	$6.5M	138	100.0%

Eversana Eversana sources from 1 verified Indian supplier across 45 distinct formulations. The sourcing is highly concentrated — Gland Pharma Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Eversana Eversana Import?

Formulation	Value	Ships
Heparin sodium injection USP 1000 USP heparin units/ML 30ML fill in a	$934.0K	21
Ketorolac tromethamine injection USP 30MG x 25 1ML	$850.0K	17
Esmolol hydrochloride in sodium chlorideinjection 2500 MG per 250ML 10MG per ML single dose	$335.1K	7
Furosemide injection usp40mg/4ML 10MG/ml4ml fill in 5ML	$300.0K	6
Adenosine injection USP 6MG/2ML 3MG/ML	$244.9K	5
Ketorolac tromethamine injection USP 15MG x 25 1ML	$200.0K	4
Chlorothiazide sodium for injection, usp500mg/vial, 20ML	$200.0K	4
Vancomycin hydrochloride for injection USP 1g/vial 20ML	$200.0K	4
Vancomycin hcl for injection USP 10g/vial100ml	$200.0K	4
Vancomycin hcl for injection USP 10g/vial,100ML	$184.2K	4
Esmolol hydrochloride in sodium chlorideinjection 2000 MG per 100ML 20MG per ML 100ML	$150.0K	3
Heparin sodium injection USP 5000 USP heparin units/ML 1ML fill in	$150.0K	3
Heparin sodium injection USP, 1000iu/mlusp heparin units/ML 30ML fill in a	$150.0K	3
Chlorothiazide sodium for injection usp500mg/vial 20ML	$150.0K	3
Foscarnet sodium injection 6g/250ML 24MG/ML	$150.0K	3

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Heparin	Cardiovascular	$2.2M	44	0.6%	10
2	Ketorolac	Analgesics & Antipyretics	$1.1M	23	1.0%	11
3	Vancomycin	Antibiotics	$950.0K	19	1.0%	10
4	Enoxaparin	Cardiovascular	$650.0K	13	0.3%	10
5	Syringe	Medical Devices & Diagnostics	$650.0K	13	0.4%	11

Eversana Eversana imports 5 pharmaceutical products across 4 categories into United States totaling $5.6M.

Eversana Eversana — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Eversana is a leading independent provider of global services to the life sciences industry, offering integrated solutions that span all stages of the product lifecycle. Founded in 1995 and headquartered in Chicago, Illinois, Eversana serves over 670 organizations, including both innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world.

The company employs a team of more than 6,000 professionals across over 20 locations worldwide. Their services are rooted in the patient experience, delivering long-term, sustainable value for patients, prescribers, channel partners, and payers.

2Distribution Network

Eversana operates a comprehensive distribution network with over 20 locations across North America, Europe, and Asia Pacific. In the United States, key facilities include offices in Chicago, Illinois; Memphis, Tennessee; Fontana, California; Chesterfield, Missouri; New York, New York; and San Diego, California.

The company's logistics capabilities are designed to support the efficient distribution of pharmaceutical products, ensuring timely delivery and compliance with regulatory standards. Their geographic coverage extends beyond the United States, enabling them to serve a global client base effectively.

3Industry Role

Eversana functions as a comprehensive service provider within the pharmaceutical supply chain, offering integrated commercial services that encompass regulatory consulting, market access strategies, patient services, and commercialization support. While they are not primarily a wholesaler or distributor, their services support pharmaceutical companies in bringing products to market and managing their lifecycle.

Their role is pivotal in facilitating the market entry and sustained success of pharmaceutical products, particularly for emerging companies seeking to navigate complex regulatory environments and market dynamics.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Eversana Eversana

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Eversana's import data indicates a significant concentration in sourcing finished pharmaceutical formulations from a single supplier, GLAND PHARMA LIMITED, which accounts for 100% of their imports from India. This single-source dependency suggests a strategic choice aimed at streamlining supply chain operations and ensuring consistency in product quality.

However, this sourcing strategy also presents potential risks, such as supply chain disruptions due to geopolitical events, regulatory changes, or operational issues within the supplier's facilities. The absence of alternative suppliers could lead to challenges in maintaining a steady product supply in the event of such disruptions.

2Supply Chain Resilience

The resilience of Eversana's Indian supply chain is closely tied to the stability and reliability of GLAND PHARMA LIMITED. The lack of backup suppliers for their imported products indicates a potential vulnerability in their supply chain. Diversifying their supplier base could mitigate risks associated with single-source dependency.

Additionally, the company's focus on finished pharmaceutical formulations imported from India suggests a reliance on specific shipping routes and regulatory compliance standards. Ensuring that GLAND PHARMA LIMITED adheres to international Good Manufacturing Practice (GMP) standards and maintains robust quality control measures is crucial for sustaining supply chain resilience.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and marketing of pharmaceutical products. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which sets forth requirements for drug safety, efficacy, and quality.

The FDA's Center for Drug Evaluation and Research (CDER) is responsible for evaluating new drugs and ensuring that they meet the necessary standards before they can be marketed in the U.S. For Indian generics, the FDA's Abbreviated New Drug Application (ANDA) pathway allows for the approval of generic drugs based on bioequivalence to an existing approved drug, facilitating market entry for these products.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in the U.S. are stringent, necessitating that all imported drugs be approved by the FDA. Manufacturers and importers must ensure that their products comply with FDA regulations, including those related to Good Manufacturing Practice (GMP).

The FDA recognizes GMP certifications from other regulatory bodies, such as the European Medicines Agency (EMA) and the World Health Organization (WHO), provided that the standards meet or exceed FDA requirements. This recognition facilitates the importation of foreign-manufactured drugs into the U.S. market.

Eversana Eversana — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Eversana's focus on importing finished pharmaceutical formulations in therapeutic categories such as cardiovascular, analgesics & antipyretics, and antibiotics aligns with market demand for these essential medications. The significant import values in these categories indicate a strategic emphasis on addressing prevalent health conditions and patient needs.

The company's import strategy is likely driven by factors such as the prevalence of cardiovascular diseases, the need for effective pain management solutions, and the ongoing demand for antibiotics to combat infections. By concentrating on these therapeutic areas, Eversana aims to meet critical healthcare needs and capitalize on market opportunities.

2Sourcing Profile

Eversana's sourcing strategy for generic drugs involves importing finished pharmaceutical formulations from a single supplier, GLAND PHARMA LIMITED, based in India. This approach suggests a preference for established suppliers with a proven track record in manufacturing high-quality generics.

India's role in Eversana's procurement strategy is significant, given the country's reputation as a major producer of generic pharmaceuticals. By sourcing from India, Eversana leverages cost advantages and access to a diverse range of generic products, enhancing its ability to meet market demands effectively.

Market Positioning

Seller's Guide — How to Become a Supplier to Eversana Eversana

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Eversana's supply chain by offering high-quality finished pharmaceutical formulations in the therapeutic areas of cardiovascular, analgesics & antipyretics, and antibiotics. By providing competitive pricing, reliable delivery schedules, and adherence to international quality standards, new suppliers can position themselves as viable partners to Eversana.

Diversifying Eversana's supplier base can mitigate risks associated with single-source dependency and enhance supply chain resilience. For Indian exporters, this presents an opportunity to expand their market reach and establish long-term partnerships with a leading player in the U.S. pharmaceutical market.

2Requirements & Qualifications

Indian exporters seeking to supply Eversana and the U.S. market must ensure that their products comply with FDA regulations, including obtaining necessary approvals and certifications. Adherence to international GMP standards, such as those recognized by the WHO, is essential to meet quality expectations.

Additionally, exporters must ensure that their products meet labeling requirements, including the use of English language on all labeling materials and compliance with serialization mandates. Staying informed about FDA regulations and maintaining compliance with evolving standards is crucial for successful market entry.

Frequently Asked Questions — Eversana Eversana

What products does Eversana Eversana import from India?

Eversana Eversana imports 5 pharmaceutical products across 4 categories. Top imports: Heparin ($2.2M), Ketorolac ($1.1M), Vancomycin ($950.0K), Enoxaparin ($650.0K), Syringe ($650.0K).

Who supplies pharmaceuticals to Eversana Eversana from India?

Eversana Eversana sources from 1 verified Indian suppliers. The primary supplier is Gland Pharma Limited (100.0% of imports, $6.5M).

What is Eversana Eversana's total pharmaceutical import value?

Eversana Eversana's total pharmaceutical import value from India is $5.6M, based on 112 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Eversana Eversana focus on?

Eversana Eversana imports across 4 categories. The largest: Cardiovascular (50.9%), Analgesics & Antipyretics (20.5%), Antibiotics (17.0%).

Get Full Eversana Eversana Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.